Trading symbol: CST
Outstanding shares: 50,261,136
Dr. Sheldon brings extensive expertise in industrial application of
enzymes to further advance the commercialization of CO2 Solution's
patented carbon capture platform
QUEBEC CITY, June 25 /CNW Telbec/ - CO2 Solution Inc. ("CO2 Solution" or
the "Company") announced today that Dr. Roger Sheldon has joined its
Scientific Advisory Board (SAB). Dr. Sheldon brings to CO2 Solution more than
three decades of experience in the industrial application of biocatalysts.
Dr. Sheldon is Professor Emeritus and the previous Chair of Biocatalysis
and Organic Chemistry at Delft University of Technology, the Netherlands, a
position he held from 1991 until 2008. Prior to this, Dr. Sheldon was
Vice-President of Research & Development for DSM N.V. a leading multi-national
life sciences and chemical company from 1980 until 1991. Dr. Sheldon is also
the founder of CLEA Technologies B.V., a top developer of proprietary enzyme
Dr. Sheldon is a respected authority on the use of biocatalysts for
industrial processes, and was the first Chairman of the Editorial Board that
established the successful journal, Green Chemistry. More recently, he was
Chairman of Biotrans 2005, the International Conference on Biocatalysis and
Chairman of the 3rd International Conference on Green and Sustainable
Chemistry (Delft, 2007). He has published more than 400 technical papers and
50 patents and six books on the subject of catalysis. Dr. Sheldon is
particularly known for his work in designing multi-step catalytic processes
which imitate the metabolic pathways in living cells.
On joining CO2 Solution, Dr. Sheldon remarked "I am very pleased to be
joining CO2 Solution's Scientific Advisory Board when the company is in the
midst of scaling up and validating its biocatalyst based technology. This is
an area where I can contribute significantly to process optimization. I
believe CO2 Solution's process is at the leading edge of harnessing the power
of nature to efficiently reduce greenhouse gas emissions"
Commenting on the appointment, Glenn Kelly, President & CEO remarked "We
are very pleased to have Dr. Sheldon join us and are lucky to have access to
his extensive experience and far-reaching track record of accomplishments in
the field of biocatalysis to further strengthen our efforts to deploy our
technology. We look forward to actively utilizing his expertise."
About CO2 Solution
Based in Quebec City, CO2 Solution Inc. has developed a proprietary
bio-technological platform for the efficient capture of carbon dioxide (CO2),
the most important greenhouse gas (GHG), from power plants and other large
stationary sources of emissions. The Company's technology platform exploits
the natural power of a bio-catalyst (enzyme), carbonic anhydrase, which
functions within humans and other mammals to manage CO2 during respiration.
CO2 Solution has successfully adapted the enzyme to function within an
industrial environment, and thus has taken advantage of a biomimetic approach
to CO2 capture based on millions of years of evolution. The Company is
commercializing its technology for coal fired power generation, the oil sands
and other CO2-intensive industries where a low-cost capture solution is key to
meeting climate change legislation in a cost effective manner.
CO2 Solution's technology platform is protected by several North American
and European patents, including the use of immobilized carbonic anhydrase for
CO2 capture and release in a packed column system. News releases and
additional information can be found at www.co2solution.com
The TSX Venture Exchange has neither approved nor disapproved the
information contained herein and accepts no responsibility for it.
For further information:
For further information: Annie Chiasson, Director, Corporate Affairs,
(418) 842-3456, email@example.com, www.co2solution.com; Source:
CO2 Solution Inc.